However, timely market entry requires integrated processes, reports Markus Burkert (pictured), Product Manager, Pharma Liquid and Sustainability, at Syntegon Technology GmbH. System providers act as technological partners and offer flexible solutions for high-volume production.
Whatever their condition, patients urgently need effective control: weight loss is the main objective for obese people, whereas type 2 diabetes requires a regulated release of insulin.
Patients with type 2 diabetes can produce insulin themselves, but often not in sufficient quantities. Medicines based on incretin mimetics are proving to be an effective treatment option for both indications.
The products are experiencing increased demand as, following recent approvals, they can also be used for weight control.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.